Propanc Health Group Corporation — Form 10-Q Summary
Period and entity: The supplied filing is for the quarter ended March 31, 2014, covering the three and nine months ended on that date. This differs from the request metadata’s “2013 Q3” and “Propanc Biopharma, Inc.”; the filing identifies the registrant as Propanc Health Group Corporation. The interim financial statements are unaudited.
Business context and financial performance
The company describes itself as a development-stage cancer-treatment research company. It reports no products available for sale and no products in clinical trials; its lead product was in preclinical activities. The statements report no revenue in either the three- or nine-month periods ended March 31, 2014 or 2013.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Operating expenses, 2014 | $104,315 | $638,338 |
| Operating expenses, 2013 | $229,367 | $1,172,127 |
| Net loss, 2014 | $66,865 | $611,977 |
| Net loss, 2013 | $337,672 | $1,217,990 |
| Cash used in operations, 2014 | Not separately stated | $137,667 |
| Cash used in operations, 2013 | Not separately stated | $96,701 |
Operating expenses and net losses were lower year over year; management attributed the operating-expense reduction mainly to lower amortization of prepaid shares issued for services. No revenue means there was no gross profit or gross margin to report. The nine-month net loss included a $27,016 gain from the change in fair value of warrant derivative liability, while interest expense was $42,291.
Financial position, debt and liquidity
- At March 31, 2014, reported cash was $40, total assets were $40, and current liabilities were $1,165,234. The balance sheet reports a working-capital deficit and stockholders’ deficit of $1,165,194; accumulated development-stage deficit was $17,335,330.
- Current liabilities included accounts payable of $332,287, accrued expenses and other payables of $373,286, loans from directors and an officer of $156,149, amounts due to directors of $57,952, and a warrant derivative liability of $111,343. Convertible notes were carried at $39,890 net of an unamortized debt discount.
- Cash used in operating activities was $137,667, offset by $136,745 of financing cash flow; ending cash was $40. The company reported no investing cash flow during the period.
- Director/officer loans and loans from two unrelated parties were described as past due and in default. The $156,149 director/officer balance bore interest at prime plus 2% (5.25% at period end); the unrelated-party loans bore 10% interest.
- A September 2013 debenture had a stated principal of $139,680, carried 12% interest, and matured December 31, 2015. It included 3,000,000 warrants with repricing provisions; the warrant liability was valued using Level 3 inputs.
Outlook, risks and other notable matters
- Management estimated that approximately $7.5 million would be needed to fund operations and the development program over the next 12 to 18 months, and stated that available cash was insufficient to continue operations for the next 12 months. It was seeking additional funding through securities sales and related-party advances, with no assurance of success.
- The filing states that the lack of revenue, operating losses, cash used in operations, working-capital deficit and defaulted loans raise substantial doubt about the company’s ability to continue as a going concern. No assurance was given that it could obtain financing, complete development, secure patent protection, or reach adequate sales.
- Research and development expense was zero for the nine months ended March 31, 2014, compared with $1,744 in the prior-year period. The company reported ongoing preclinical work and patent filings; it said a patent had been granted in South Africa.
- Disclosure controls and procedures were assessed as ineffective due to a material weakness: insufficient segregation of duties because of the company’s small staff. Management said it planned to address this by hiring accounting personnel when resources permitted.
- The filing reported no material pending or threatened litigation, no off-balance-sheet arrangements, and no changes in internal control over financial reporting during the quarter. A $2,774 CEO loan was received in April 2014.
Key facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied filing names Propanc Health Group Corporation and ends March 31, 2014, not Propanc Biopharma, Inc. or a 2013 quarter.
- Reconcile the reported $40 cash balance and zero bank overdraft with MD&A language describing a “negative cash balance.”
- Assess near-term funding requirements, the stated $7.5 million development-funding estimate, and the consequences of the going-concern uncertainty.
- Review the status, terms and default status of related-party and unrelated-party loans, and the valuation and repricing provisions of the convertible debenture warrants.
- Verify development and patent milestones, including the gap between stated preclinical activity and zero reported R&D expense for the nine-month period.